三级淋巴结构评估胃癌免疫治疗疗效的研究
该单中心回顾性研究纳入33例接受免疫治疗的胃癌患者,用HE和免疫组化评估TLS浸润及CD3、CD20、PNAd、BCL6表达,发现TLS高浸润和BCL6高表达与更高的ORR、DCR及更长PFS相关,TLS浸润水平为独立保护因素,两者AUC均较高。
要点
- TLS高浸润组ORR 58.8% vs 18.8%,DCR 94.1% vs 37.5%,中位PFS 276 vs 67天。
- BCL6高表达组ORR 64.7% vs 12.5%,DCR 100.0% vs 31.3%,中位PFS显著延长。
- TLS浸润水平为独立保护因素(HR=0.147,95%CI 0.022-0.964,P=0.046)。
核心结论
- TLS浸润度和BCL6表达水平可作为胃癌免疫治疗潜在的预测与预后生物标志。
研究设计与样本
- 单中心回顾性研究,收集2020年1月至2024年12月在东南大学附属中大医院接受免疫治疗的33例胃癌患者临床病理资料及组织样本。
- 采用HE染色及免疫组化评估TLS浸润程度及CD3、CD20、PNAd和BCL6表达水平。
主要发现
- TLS高浸润组ORR为58.8%(10/17),低浸润组为18.8%(3/16),P=0.019。
- TLS高浸润组DCR为94.1%(16/17),低浸润组为37.5%(6/16),P<0.001。
- BCL6高表达组ORR为64.7%(11/17),低表达组为12.5%(2/16),P=0.004。
- BCL6高表达组DCR为100.0%(17/17),低表达组为31.3%(5/16),P<0.001;中位PFS显著延长(P<0.001)。
关键数值与推荐
- 多因素Cox回归显示TLS浸润水平是独立保护因素(HR=0.147,95%CI:0.022~0.964,P=0.046)。
- ROC曲线显示TLS浸润度预测疗效的AUC=0.885(P<0.001)。
- BCL6评分模型预测疗效的AUC=0.890(P<0.001)。
临床怎么用
- 对接受免疫治疗的胃癌患者,可评估TLS密度和BCL6表达以辅助筛选潜在获益人群。
- TLS高浸润或BCL6高表达提示免疫治疗应答和生存获益可能性更高。
局限性
- 样本量仅33例,为单中心回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the prognostic and predictive value of tertiary lymphoid structures (TLS) in gastric cancer patients undergoing immunotherapy. Methods: Clinical and pathological data, along with tumor tissue samples, were collected from 33 gastric cancer patients who received immunotherapy at Zhongda Hospital, Southeast University from January 2020 to December 2024. The density of tertiary lymphoid structures (TLS) and expression patterns of CD3, CD20, PNAd, and BCL6 were systematically evaluated using hematoxylin-eosin (H&E) staining and immunohistochemical (IHC) analysis. Statistical analyses were performed to determine the associations between TLS characteristics and clinical outcomes, including objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). Results: Patients in the TLS-high infiltration group (TLSHigh) demonstrated significantly better outcomes compared to that of the TLS-low group (TLSLow), with higher ORR (58.8% vs 18.8%, P=0.019), DCR (94.1% vs 37.5%, <0.001), and markedly prolonged median PFS (276 vs 67 days, P<0.000 1). Similarly, the BCL6-high expression group (BCL6High) showed superior treatment responses versus the BCL6-low group (BCL6Low), with significantly higher ORR (64.7% vs 12.5%, P=0.002), DCR (100.0% vs 31.3%, P<0.001), and extended PFS (P<0.001). Univariate and multivariable Cox regression confirmed TLS infiltration level as an independent favorable prognostic factor for gastric cancer patients receiving immunotherapy (HR=0.147, 95% CI: 0.022-0.964, P=0.046). Receiver operating characteristic (ROC) curve analysis revealed excellent predictive accuracy for both TLS infiltration [area under the curve (AUC)=0.885, P<0.001] and the BCL6 scoring model (AUC=0.890, P<0.001) in anticipating immunotherapy response. Conclusion: TLS density and BCL6 expression may serve as dual predictive and prognostic biomarkers for gastric cancer immunotherapy, highlighting their clinical utility in patient stratification and treatment guidance. 目的: 探索三级淋巴结构(TLS)对于胃癌免疫治疗的预后和预测价值。 方法: 收集2020年1月至2024年12月在东南大学附属中大医院接受免疫治疗的33例胃癌患者的临床病理资料及组织样本,采用HE染色及免疫组织化学染色方法评估TLS浸润程度及CD3、CD20、PNAd和BCL6的表达水平,分析其与客观缓解率(ORR)、疾病控制率(DCR)和无进展生存时间(PFS)的相关性,影响因素分析采用Cox比例风险模型。 结果: TLS高浸润组的ORR[分别为58.8%(10/17)和18.8%(3/16),P=0.019]和DCR[分别为94.1%(16/17)和37.5%(6/16),P<0.001]均显著高于TLS低浸润组,且中位PFS(分别为276和67 d,P<0.000 1)显著延长;BCL6高表达组的ORR[分别为64.7%(11/17)和12.5%(2/16),P=0.004]和DCR[分别为100.0%(17/17)和31.3%(5/16),P<0.001]均显著高于BCL6低表达组,且中位PFS显著延长(P<0.001)。多因素Cox回归分析结果显示,TLS的浸润水平是影响胃癌免疫治疗预后的独立保护因素(HR=0.147,95% CI:0.022~0.964,P=0.046)。受试者操作特征曲线表明,TLS浸润度[曲线下面积(AUC)=0.885,P<0.001]及BCL6评分模型(AUC=0.890,P<0.001)能准确预测胃癌患者接受免疫治疗的疗效。 结论: TLS浸润度和BCL6表达水平可作为胃癌免疫治疗潜在的预测与预后生物标志,提示其在筛选获益人群及指导治疗决策中具有重要应用前景。.
引用
- Li SF, Zhang HJ. [Research on the evaluation of the efficacy of immunotherapy for gastric cancer by tertiary lymphoid structures]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 41130783. doi:10.3760/cma.j.cn112152-20250518-00229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。